Diffuse Scleroderma, Limited Scleroderma
Conditions
Keywords
limited scleroderma, diffuse scleroderma, Sclerosis, Progressive, Limited
Brief summary
To treat patients with scleroderma by blocking the expression of LOXL2. The investigators first need to confirm (through observation) that LOXL2 is overexpressed in disease.
Detailed description
Scleroderma is a chronic skin-hardening disease. There are two types of scleroderma. The first type is called limited cutaneous scleroderma, where disrupted blood flow causes skin discoloration and sometimes patients experience high blood pressure in their arteries. The second type is called diffuse cutaneous scleroderma and it is much more aggressive, affecting a larger area of skin causing organ damage. This study will determine if the disease is associated with an elevated expression of LOXL2 levels in tissue samples from patients.
Interventions
None listed
Sponsors
Gilead Sciences
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Over 18 years of age * Documented diagnosis of scleroderma * Willing and able to provide written informed consent
Exclusion criteria
* Use of experimental therapies within 28 days prior to Screening. * Aspirin use \> 81 mg daily within 1 week prior to Screening. * Any lab abnormality or concurrent medical condition that, in the opinion of the investigator would make the patient ineligible for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Summarized the number and percentage of subjects with elevated LOXL2 levels | Baseline |
Countries
Australia
Outcome results
None listed